We are live on
!
Find out more
VM
VHCP Management Portfolio holdings
AUM
$93M
1-Year Est. Return
10.04%
This Fund
S&P 500
This Quarter
Est. Return
-2.33%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$165M
AUM Growth
-$225M
(-58%)
Cap. Flow
-$200M
Cap. Flow
% of AUM
-121.14%
Top 10 Holdings %
Top 10 Hldgs %
89.08%
Holding
21
New
3
Increased
–
Reduced
13
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$2.63M |
| 2 |
PDS Biotechnology
PDSB
|
+$2.18M |
| 3 |
CytomX Therapeutics
CTMX
|
+$1.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$114M |
| 2 |
Regenxbio
RGNX
|
+$20.5M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$12.6M |
| 4 |
AKTX
Akari Therapeutics
AKTX
|
+$6.86M |
| 5 |
Coherus Oncology
CHRS
|
+$6.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.71% |
| 2 | Miscellaneous | 30.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Heron Therapeutics
HRTX
$63M
| $29.3M | 17.68% |
1,095,734
| – | – |
|
|
GWPH
2
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $21.7M | 13.09% |
311,853
| – | – |
|
|
ANAC
3
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $15.9M | 9.61% |
140,756
-1,037,718
| -88% | -$114M |
|
|
4
Coherus Oncology
CHRS
$226M
| $14M | 8.48% |
611,010
-259,259
| -30% | -$6.67M |
|
5
Lipocine
LPCN
$18.4M
| $11M | 6.64% |
49,995
-24,706
| -33% | -$5.18M |
|
|
ADVM
6
DELISTED
Adverum Biotechnologies
ADVM
| $10.5M | 6.35% |
110,274
-28,000
| -20% | -$2.46M |
|
|
AVDL
7
DELISTED
Avadel Pharmaceuticals
AVDL
| $6.11M | 3.69% |
500,000
| – | – |
|
8
Larimar Therapeutics
LRMR
$421M
| $3.41M | 2.06% |
45,123
| – | – |
|
9
Arcturus Therapeutics
ARCT
$460M
| $3.04M | 1.84% |
69,214
-145,072
| -68% | -$6.53M |
|
|
AKTX
10
Akari Therapeutics
AKTX
$17.5M
| $2.3M | 1.39% |
198
-462
| -70% | -$6.86M |
|
|
OCRX
11
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $2.2M | 1.33% |
703,730
| – | – |
|
|
ORKA
12
Oruka Therapeutics
ORKA
$6.39B
| $2.15M | 1.3% |
2,141
-4,995
| -70% | -$5.66M |
|
|
GBT
13
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $1.96M | 1.19% |
+60,691
| New | +$2.63M |
|
|
14
PDS Biotechnology
PDSB
$12.2M
| $1.69M | 1.02% |
+6,750
| New | +$2.18M |
|
|
15
Ascendis Pharma A/S
ASND
$16.4B
| $1.65M | 1% |
90,000
-721,152
| -89% | -$12.6M |
|
|
16
CytomX Therapeutics
CTMX
$745M
| $1.56M | 0.95% |
+75,000
| New | +$1.19M |
|
|
SRRA
17
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.13M | 0.68% |
1,875
-4,375
| -70% | -$2.96M |
|
|
18
Regenxbio
RGNX
$619M
| $872K | 0.53% |
52,500
-1,030,954
| -95% | -$20.5M |
|
|
STML
19
DELISTED
Stemline Therapeutics, Inc.
STML
| $855K | 0.52% |
135,420
-315,980
| -70% | -$2.56M |
|
Similar funds
QGI
KC
RSCM
ZC
TF
SAM
NA
NCIM
VHCP Management's Q4 2015 Portfolio in Review
As of Q4 2015, VHCP Management held 21 positions worth $165M, down 58% from $390M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
VHCP Management withdrew a net $200M in Q4 2015, reducing 13 holdings. Its largest reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $114M.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 51% a quarter earlier, followed by Miscellaneous.
Against the trend, VHCP Management opened a new position in Global Blood Therapeutics, Inc. worth $1.96M.
- VHCP Management's largest Q4 2015 buy was Global Blood Therapeutics, Inc.: 60,691 shares worth $1.96M.
- VHCP Management's biggest Q4 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $114M.
- VHCP Management's ten largest holdings make up 89% of its $165M portfolio in Q4 2015.
- VHCP Management opened 3 new positions and closed 0 in Q4 2015.
- VHCP Management's portfolio value fell 58% quarter-over-quarter to $165M.
Based on VHCP Management's 13F filing for Q4 2015, filed 12 Feb 2016.